Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.

Hims & Hers Health Stock Soared This Week: Here's Why

Bloom Energy

As the saying goes, always follow the money. This time, investors can follow the proverbial big players through an options activity screener, spotting unusual trends in how markets are betting.

Call Option Volumes Spiked For These 3 Stocks

Enovis Corp

Health Catalyst Inc

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.

The Ultimate Growth Stock to Buy With $20 Right Now

ACM Research

Advanced Micro Devices

Intel

NVIDIA

SoFi Technologies

Block

If you're wondering which stocks to buy for the next economic upturn, you're in the right place. Finding profitable investment opportunities in the constantly changing global economy is crucial to profiting from the next economic boom.

7 Stocks to Dominate in the Next Economic Upturn

Mangoceuticals Inc

Nestle SA

For investors looking at companies providing GLP-1 drugs, there are certainly plenty of factors to consider. This is a fast-growing market, but one also becoming increasingly competitive.

Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.

ChargePoint Holdings

Virgin Galactic

Judging which growth stocks are good long-term bets is trickier than you might expect. These fast-moving businesses can be hard to forecast, and changes in their broader industries could quickly lift up (or sink) these growth names in short order.

The Growth Stock Shuffle: 2 to Ditch and 1 to Own

GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.

Hims & Hers Is Changing the Game

Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.

Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy

Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.

Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages

Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry. Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

Weight loss drugs helped Hims & Hers Health (NYSE:HIMS) put value on, with the stock soaring some 30% higher in ‘afterhours' trade on Monday. The online consumer healthcare brand last night announced it will sell lower-priced GLP-1 weight loss injectables and oral weight loss medication in the United States, through a deal with its pharmacy supplier.

Weight loss drug roll-out sends Hims & Hers stock soaring

Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs.

Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs

Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.

Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy

Shares of Hims & Hers Health (NYSE: HIMS ) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections. Hims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable medications to provide the injections.

HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections

Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11.

Hims & Hers Adds Weight-Loss Injections, Stock Soars

Hims & Hers Health Inc shares rocketed 31% higher on Monday after announcing it will provide access to injectable GLP-1 medications. These injections serve as a more affordable alternative to branded versions such as Wegovy and Ozempic, said the telehealth company in a press statement.

Hims & Hers rallies after announcing access to GLP-1 injections

Hims & Hers Health Inc.'s stock HIMS, +32.81% jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded GLP-1 drugs — products that the Food and Drug Administration has warned against.

Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings

Hims & Hers Health (NYSE: HIMS) stock price is doing well, helped by its strong growth and demand for its core products. It soared by over 30% this year and by more than 112% this year.

The case for the overvalued Hims & Hers stock

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is Hims & Hers Health (HIMS) a Buy as Wall Street Analysts Look Optimistic?

The GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.

Hims & Hers Health adds compounded GLP-1 injections to weight loss program

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment. The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience. Providing access to compoun.

Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers

Palantir Technologies

With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding.

Stock Market Mayhem: 3 Companies Ready to Shake Things Up

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company's Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official. “Anja is a remarkable leader and v.

Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Hims & Hers Health Stock (HIMS)